Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model

Anti-Cancer Drugs

Volumn 14, Issue 1, 2003, Pages 39-47

  Knapp, Derek C ^a   Mata, John E ^a   Reddy, Muralimohan T ^a   Devi, Gayathri R ^a   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

Antisense; c myc; Lung cancer; Phosphorodiamidate Morpholino oligomer

Indexed keywords

ANTINEOPLASTIC AGENT; AVI 4126; CISPLATIN; COMPLEMENTARY DNA; ETOPOSIDE; FLUOROURACIL; MYC PROTEIN; OLIGOMER; PACLITAXEL; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; PROTEIN; PROTEIN P21; RAD51 PROTEIN; RIBONUCLEASE H; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; DNA, ANTISENSE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; MICE; MICE, INBRED C57BL; MORPHOLINES; PROTO-ONCOGENE PROTEINS C-MYC; RATS;

EID: 0037265429     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200301000-00006     Document Type: Article

References (42)

1. Cook RM, Miller YE, Bunn Jr PA. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Prob Cancer 1993; 2:69-141.
2. Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res 1994; 1:281-287.
3. van Waardenburg RC, Meijer C, Pinto-Sietsma SJ, de Vries EG, Timens W, Mulder NM. Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines. Anticancer Res 1998; 1A:91-95.
4. Broers JL, Viallet J, Jensen SM, Pass H, Travis WD, Minna JD, et al. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 1993; 1:33-43.
5. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993; 2:105-127.
6. Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M, et al. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg 2001; 4:197-203.
7. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and defective myeloid leukemic cells. Cell Growth Different 1993; 1:41-47.
8. Dong J, Naito M, Tsuruo T. c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells. Oncogene 1997; 6:839-847.
9. Barr LF, Campbell SE, Diette GB, Gabrielson EW, Kim S, Shim H, et al. c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression. Cancer Res 2000; 1:143-149.
10. Funato T, Kozawa K, Kaku M, Sasaki T. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells. Anti-Cancer Drugs 2001; 10:829-834.
11. Sklar MD, Prochownik EV. Modulation of cisplatinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res 1991; 8:2118-2123.
12. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, et al. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 1991; 2:237-241.
13. 195mPt-radiolabeled cis-diaminedichloroplatinum (II) of SHOK cells transfected with various oncogenes. Radiat Med 1998; 4:233-237.
14. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev 1997; 7:187-195.
15. Summerton J, Stein D, Huang SB, Matthews P, Weller D, Partridge M. Morpholino and phosphorothioate oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 1997; 7:63-70.
16. Giles GV, Spiller DG, Clark RE, Tidd DM. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev 1999; 9:213-220.
17. Ghosh C, Stein D, Weller DD, Iversen PL. Evaluation of antisense mechanisms of action. Methods Enzymol 1999; 313:135-143.
18. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 1996; 6:267-272.
19. Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, et al. c-Myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J Pharmacol Exp Ther 2000; 292:921-928.
20. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-Myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 2002; 91:1-10.
21. Devi GR, Oldenkamp JR, London CA, Iversen PL. Inhibition of human chorionic gonadotropin β-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 2002; 53:200-210.
22. Long SE, Martin TD. Determination of trace elements in waters and wastes by inductively coupled plasma-mass spectrometry. EPA Method 200.8. Cincinnati, OH: USEPA; 1998.
23. Cito G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, et al. C-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998; 56:283-289.
24. Leonetti C, Biroccio A, Candiloro A. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistent to cisplatin. Clin Cancer Res 1999; 9:2588-2595.
25. Gazdar AF, Carbone BP. Neuroendocrine (NE) tumors of the lung. In: Gazdar AF, Carbone DP (editors): The Biology and Molecular Genetics of Lung Cancer. Austin, TX: Landes; 1994, pp. 16-26.
26. Prins J, De Vries EGE, Mulder NH. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res 1993; 13:1373-1386.
27. Prendergast GC. Myc and myb: are the veils beginning to lift? Oncogene 1999; 18:2914-2915.
28. Van Waardenburg RC, Prins J, Meijer C, Uges DR, De Vries EG, Mulder NH. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res 1996; 4:1963-1970.
29. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, et al. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 1991; 51:1708-1712.
30. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res 1991; 51:4505-4510.
31. Prins J, De Vries EG, Mulder NH. The myc family of oncogenes and their presence and importance in small cell lung carcinoma and other tumor types. Anticancer Res 1993; 13:1373-1385.
32. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistent to cisplatin. Clin Cancer Res 1999; 5:2588-2595.
33. Akie K, Dosaka-Akita H, Murakami A, Kawakami Y. A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer. Antisense Nucleic Acid Drug Dev 2000; 10:243-249.
34. D'Cruz CM, Gunther EJ, Boxer RB, Sintasath L, Moody SE, Boxer RB, et al. C-myc induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001; 7:235-239.
35. Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res 2001; 61:1178-1186.
36. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489:69-84.
37. Iversen PL. PMO: favorable properties for sequence-specific inactivation. Curr Opin Mol Ther 2001; 3:235-238.
38. Hudziak RM, Summerton J, Weller DD, Iversen PL. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev 2000; 10:163-176.
39. Ricker JL, Mata JE, Iversen PL, Gattone VH. C-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 2002;16:125-131.
40. Kipshidze N, Keane E, Stein D, Chawla P, Skrinska V, Shankar LR, et al. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv 2001; 54:247-256.
41. Devi GR. Prostate cancer: status of current treatments and emerging antisense-based therapies. Curr Opin Mol Ther 2002; 2:138-148.
42. Onoda JM, Nelson KK, Taylor JD, Honn KV. Cisplatin and nifedipine: synergistic antitumor effects against an inherently cisplatin-resistant tumor. Cancer Lett 1988; 40:39-47.